Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

Bionomics Limited
BNO
http://www.bionomics.com.au
Biotechnology
178
418

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.43 $0.43 $0.44 $0.43 $0.43 122852 - ( No change )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Current Broker Consensus Recommendation

Strong Buy
01/07/2015
1

Company Overview

Business Description
Bionomics Limited (BNO) is an Australian biotechnology company focused on the discovery and development of cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. BNO partners with pharmaceutical companies to get the drugs through the later stages of development and into the market.
Strategy Analysis
BNO seeks to develop compounds to successful proof of concept in human clinical trials. The company is open to partnership at all stages of development. Additionally, BNO is open to in-licensing proposals that are in alignment with the company's overall therapeutic focus in cancer, inflammatory disorders and CNS diseases.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016 F 0.0 10.4 0.0% 4.1 0.0 0.0% 0.0%
2015 F 0.0 -2.9 0.0% 0.0 0.0 0.0% 0.0%
2014 A 3.2 0.8 0.0% 79.8 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Bionomics (BNO) $178M 0.0000 0.0000 0.0000 55.1948 0.0000 4.0787 0.00% 0.00% 0.00%
CSL (CSL) $41,161M 0.0899 0.3345 0.0817 30.9973 23.2274 21.4729 1.35% 1.80% 2.05%
Mesoblast (MSB) $1,307M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $318M 0.0000 1.7120 0.3828 36.6848 13.5271 9.7826 0.00% 4.81% 6.64%
Sirtex Medical (SRX) $1,736M 0.2906 0.6077 0.6093 74.3584 46.2500 28.7385 0.46% 0.63% 1.03%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.66 0.00 3.96 0.00
Market 1.04 13.40 1.04 0.55
Sector 0.92 13.20 3.25 0.96

Directors

Name Position Start Date
Dr Deborah Ann Rathjen Chief Executive Officer, Managing Director 21/06/2000
Mr Trevor Tappenden Non-Executive Director 15/09/2006
Dr Errol De Souza Non-Executive Director 28/02/2008
Dr Jonathan Lim Non-Executive Director 14/09/2012
Mr Graeme Kaufman Non-Executive Director, Non-Executive Chairman 18/09/2012

Management

Name Position
Melanie Young Chief Financial Officer,Company Secretary
Jose Iglesias Chief Medical Officer
Jack Moschakis Company Secretary,Legal Councel
Emile Andriambeloson Head of Research, Neurofit
Peter Chu Vice President US Operations & Cancer Biology

Substantial Shareholders

Holding Name
40,187,873 (9.63%) Link Traders (Aust) Pty Limited
24,241,071 (5.81%) John Leaver
24,000,000 (5.75%) Ausbil Dexia Limited
21,642,425 (5.19%) Australian National University

Calendar of Events

Date Event
22 February 2016 Report (Interim)
09 October 2015 Report (Annual)
18 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.